ArticleBMC rheumatology2026
Clinical and genetic characteristics of adult patients with familial Mediterranean fever at a German tertiary referral centre.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterise the clinical and genetic profile of adult familial Mediterranean fever (FMF) patients at a German tertiary referral centre and examine genotype-phenotype associations.
methodsIn this prospective single-centre registry study (October 2019-March 2021), 95 adult FMF patients at University Hospital Tübingen were evaluated using structured questionnaires and medical record review. All patients had a pre-existing clinical diagnosis of FMF based on the Tel Hashomer and/or Eurofever/PRINTO criteria. Demographic data, clinical manifestations, treatment, and MEFV mutations were analysed. Patients were stratified by mutation status (homozygous M694V, heterozygous/compound-heterozygous M694V, other mutations). Statistical analyses included the Fisher-Freeman-Halton exact test and ANOVA. Variants were classified according to the INSAID consensus classification; R202Q was treated as a benign polymorphism. All subgroup comparisons were exploratory and were not corrected for multiple testing.
resultsMedian age was 36 years, with median symptom onset at 10 years. Most patients were of Turkish origin (74.7%), and 59.6% reported a family history of FMF. Common manifestations included abdominal pain (90.5%), arthralgia/arthritis (75.8%), fever (66.3%), and chest pain (52.6%). Colchicine was used in 96.8% of patients, while 38.3% received biologic therapy, a figure influenced by concurrent participation in a tocilizumab trial at our centre. MEFV analysis had been performed in 91 of the 95 patients (95.8%); among these, at least one MEFV variant was detected in 87 (95.6%), with M694V being the most frequent variant (61.5%). Homozygous M694V patients showed earlier disease onset (nominal p = 0.02) and higher rates of arthralgia/arthritis (nominal p = 0.035). Amyloidosis occurred in one patient with homozygous M694V.
conclusionThis cohort demonstrates typical FMF features with a predominance of the M694V mutation. Homozygosity for M694V is associated with earlier disease onset and increased musculoskeletal involvement. Subgroup findings are exploratory and require confirmation in independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.